Researchers at the University of Michigan have published a study suggesting that dietary changes could improve outcomes for patients with glioblastoma, a deadly form of brain cancer. The study indicates that a low-protein diet, coupled with protein shakes free from the amino acid serine, may make tumors more vulnerable to chemotherapy and radiation treatments.
Glioblastoma is notoriously difficult to treat due to its aggressive nature and resistance to standard therapies. The new research, conducted in animal models, shows that restricting dietary serine and glycine—amino acids found in protein—can disrupt the metabolism of glioblastoma cells, making them more sensitive to chemoradiation. The study team notes that more research is needed before these findings can be tested in humans, but the approach holds promise as a non-invasive way to enhance existing treatments.
The findings come as other companies, like CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are exploring novel therapies for brain cancer. CNS Pharmaceuticals is developing treatments for glioblastoma and other central nervous system cancers, highlighting the ongoing efforts to combat this challenging disease.
The University of Michigan study adds to a growing body of evidence that diet can influence cancer treatment outcomes. By targeting the metabolic vulnerabilities of cancer cells, researchers hope to improve the efficacy of standard therapies without adding toxicity. The low-protein diet approach is particularly attractive because it is relatively simple and could be implemented alongside existing treatment protocols.
The study was published in a peer-reviewed journal and has garnered attention from the medical community. While the results are preliminary, they underscore the potential of dietary interventions in oncology. The researchers emphasize that patients should not attempt such diets without medical supervision, as protein restriction can have side effects and must be carefully managed.
For more information on the latest developments in biotechnology and life sciences, visit BioMedWire, a platform that covers breaking news in the biotech sector. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides corporate communications solutions to a wide range of industries.
